Stock Rating Upgrade
Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for Supernus Pharmaceuticals Inc (NASDAQ: SUPN) improved of late. SUPN’s current Value Trend Rating is C and the prior Rating was D. Details supporting this higher rating are included in our next report.
Recent Price Action
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock closed at $28.96 on 5/10/24 after a decline of -3.5%. Moreover, trading volume in this decline was exceptionally high at 215% of normal. The stock has declined -4.3% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
SUPN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Supernus Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Supernus Pharmaceuticals has a neutral Power Rating of 48 and a neutral Appreciation Score of 44, producing the Low Neutral Value Trend Rating.
Be the first to comment